PA
ATRA icon

Perceptive Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Perceptive Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,404
Closed -$581K – 136
2017
Q3 		$581K Buy
+1,404
New +$529K 0.02% 117
2016
Q3 		– Sell
-100
Closed -$56K – 195
2016
Q2 		$56K Buy
+100
New +$48K ﹤0.01% 159

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Perceptive Advisors's ATRA Position: Q4 2017 in Review

Perceptive Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2017, closing a stake of 1,404 shares — an estimated $581K sold.

Perceptive Advisors first reported a position in ATRA in Q2 2016 and held it in 2 quarters. The position peaked at $581K in Q3 2017. 86 funds tracked by Wall St. Rank hold ATRA as of Q4 2017.

  • Perceptive Advisors reported no remaining Atara Biotherapeutics position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 1,404 Atara Biotherapeutics shares in Q4 2017, an estimated $581K.
  • Perceptive Advisors first reported a position in Atara Biotherapeutics in Q2 2016 and held it in 2 quarters.
  • Perceptive Advisors's Atara Biotherapeutics position peaked at $581K in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.